DC Chemicals Limited
China
Product Name: Lanraplenib monosuccinate
Price: $Inquiry/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao
Email: sales@dcchemicals.com

1800046-97-2

1800046-97-2 structure

Name: Lanraplenib monosuccinate
Chemical Name: Lanraplenib monosuccinate
CAS Number: 1800046-97-2
Molecular Formula: C₂₇H₃₁N₉O₅
Molecular Weight: 561.59
Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK Syk
Create Date: 2019-12-07 17:38:54
Modify Date: 2024-01-11 19:28:22
Lanraplenib monosuccinate (GS-9876 monosuccinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans[1][2][3].

Name	Lanraplenib monosuccinate

Description	Lanraplenib monosuccinate (GS-9876 monosuccinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans[1][2][3].
Related Catalog	Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Syk
Target	IC50: 9.5 nM (SYK)[1]
In Vitro	Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits anti-IgM stimulated phosphorylation of AKT, BLNK, BTK, ERK, MEK, and PKCδ in human B cells with EC50 values of 24-51 nM. Lanraplenib monosuccinate inhibits anti-IgM mediated CD69 and CD86 expression on B-cells (EC50=112±10 nM and 164±15 nM, respectively) and anti-IgM /anti-CD40 co-stimulated B cell proliferation (EC50=108±55 nM). In human macrophages, Lanraplenib monosuccinate inhibits IC-stimulated TNFα and IL-1β release (EC50=121±77 nM and 9±17 nM, respectively)[1]. Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits glycoprotein VI (GPVI)-induced phosphorylation of linker for activation of T cells and phospholipase Cγ2, platelet activation and aggregation in human whole blood, and platelet binding to collagen under arterial flow[2].
References	[1]. Di Paolo J, et al. FRI0049 Preclinical Characterization of GS-9876, A Novel, Oral SYK Inhibitor That Shows Efficacy in Multiple Established Rat Models of Collagen-Induced Arthritis.Annals of the Rheumatic Diseases 2016;75:443-444. [2]. Clarke AS, et al. Effects of GS-9876, a novel spleen tyrosine kinase inhibitor, on platelet function and systemic hemostasis. Thromb Res. 2018 Oct;170:109-118. [3]. Kivitz AJ, et al. GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients with Active Rheumatoid Arthritis: Safety, Tolerability and Efficacy Results of a Phase 2 Study [abstract]. Arthritis Rheumatol.2018; 70 (suppl 10).

Molecular Formula	C₂₇H₃₁N₉O₅
Molecular Weight	561.59

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

1800046-97-2	1800046-95-0
1800047-00-0	1001229-71-5
111755-48-7	56-14-4
216167-82-7	3544-94-3
982-57-0	102696-21-9
2365471-02-7	2365470-97-7
2382295-26-1	2151025-56-6
2177264-82-1	1951442-13-9
2177264-62-7	1821770-25-5
1228449-80-6	2287247-22-5